Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$192 Mln
P/E Ratio
--
P/B Ratio
0.79
Industry P/E
--
Debt to Equity
0.01
ROE
-0.19 %
ROCE
-18.91 %
Div. Yield
0 %
Book Value
4.28
EPS
-0.88
CFO
$-148.06 Mln
EBITDA
$-191.31 Mln
Net Profit
$-171.34 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
| -43.27 | -25.61 | -26.16 | -5.15 | -38.76 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Design Therapeutics (DSGN)
| 131.23 | -74.17 | -52.08 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC... platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. Address: 6005 Hidden Valley Road, Carlsbad, CA, United States, 92011 Read more
Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
Mr. Pratik Shah Ph.D.
Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
Mr. Pratik Shah Ph.D.
Headquarters
Carlsbad, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Design Therapeutics Inc (DSGN) stood at $ 252 Mln as on 31-Dec-24
The share price of Design Therapeutics Inc (DSGN) is $3.50 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Design Therapeutics Inc (DSGN) has given a return of -38.76% in the last 3 years.
Design Therapeutics Inc (DSGN) has a market capitalisation of $ 192 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Design Therapeutics Inc (DSGN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Design Therapeutics Inc (DSGN) and enter the required number of quantities and click on buy to purchase the shares of Design Therapeutics Inc (DSGN).
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. Address: 6005 Hidden Valley Road, Carlsbad, CA, United States, 92011
The CEO & director of Mr. Pratik Shah Ph.D.. is Design Therapeutics Inc (DSGN), and CFO & Sr. VP is Mr. Pratik Shah Ph.D..
There is no promoter pledging in Design Therapeutics Inc (DSGN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Design Therapeutics Inc. (DSGN) | Ratios |
|---|---|
|
Return on equity(%)
|
-19.08
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Design Therapeutics Inc (DSGN) was $0 Mln.
$0.12
(
